Abstract |
The efficacy of bleomycetin or bleomycin A5 was studied in 128 patients with different malignant neoplasms. The antibiotic was used as a systemic or intracavitary chemotherapeutic agent. Bleomycetin was effective in 75-80, 81.8, 58.3, 70 and 50 per cent of the cases with disseminated derminogenic tumor of the testicle, squamous cell carcinoma of the head and neck, cancer of the penis, carcinoma of the skin and lymphogranulomatosis, respectively. When used intracavitarily the drug was effective in 41.2 per cent of the patients with cancer of the ovaries and lungs, teratoblastoma of the ovaries, cancer of the mammary gland and sarcoma of the soft tissues. Hyperthermia and focal hyperkeratosis as the adverse reactions were observed in 40.6 and 5.4 per cent of the patients, respectively. No toxicity with respect to the lungs was registered.
|
Authors | L V Manziuk, N I Perevodchikova |
Journal | Antibiotiki
(Antibiotiki)
Vol. 27
Issue 5
Pg. 372-7
(May 1982)
ISSN: 0003-5637 [Print] Russia (Federation) |
Vernacular Title | Klinicheskaia otsenka protivo-opukholevogo antibiotika iz gruppy bleomitsinov-bleomitsetina. |
PMID | 6179464
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Bleomycin
- bleomycetin
|
Topics |
- Adolescent
- Adult
- Aged
- Antibiotics, Antineoplastic
(administration & dosage, adverse effects, therapeutic use)
- Bleomycin
(administration & dosage, adverse effects, therapeutic use)
- Child
- Child, Preschool
- Clinical Trials as Topic
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Time Factors
|